1. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol 2012;27:1266–80.
2. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013;145:158–65. e2.
3. Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, et al. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol 2010;45:1178–85.
5. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508–30.
6. Bergstrand O, Ewerth S, Hellers G, Holmström B, Ullman J, Wallberg P. Outcome following treatment of anal fistulae in Crohn’s disease. Acta Chir Scand Suppl 1980;500:43–4.
8. Chung W, Ko D, Sun C, Raval MJ, Brown CJ, Phang PT. Outcomes of anal fistula surgery in patients with inflammatory bowel disease. Am J Surg 2010;199:609–13.
9. El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas. Colorectal Dis 2012;14:1217–23.
10. Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn’s disease. Dis Colon Rectum 2005;48:459–63.
11. Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br J Surg 2004;91:476–80.
12. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405.
13. Sciaudone G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, et al. Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach. Can J Surg 2010;53:299–304.
16. Antakia R, Shorthouse AJ, Robinson K, Lobo AJ. Combined modality treatment for complex fistulating perianal Crohn’s disease. Colorectal Dis 2013;15:210–6.
17. Haennig A, Staumont G, Lepage B, Faure P, Alric L, Buscail L, et al. The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn’s disease. Colorectal Dis 2015;17:311–9.
18. Duff S, Sagar PM, Rao M, Dolling S, Sprakes M, Hamlin PJ. Infliximab and surgical treatment of complex anal Crohn’s disease. Colorectal Dis 2012;14:972–6.
19. Bouguen G, Siproudhis L, Gizard E, Wallenhorst T, Billioud V, Bretagne JF, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 2013;11:975–81. e1-4.
20. Hanauer SB. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for “step-up” versus “top-down”. Rev Gastroenterol Disord 2007;7 Suppl 2:S17–22.
21. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology 2010;138:463–8.
22. D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008;371:660–7.
23. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85.